A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis

NCT ID: NCT01373567

Last Updated: 2012-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

298 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-12-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Psoriasis is a chronic inflammatory hyperproliferative disease of the skin affecting approximately 2% of the world's population.This phase IV study is planned to monitor performance of Tinefcon in patients suffering from psoriasis under conditions of actual use and fulfill requirements to monitor all adverse drug reactions (ADRs) in psoriasis patients treated with Tinefcon. This study will add to literature on the risks and benefits of Tinefcon the novel oral TNF-alpha release inhibitor.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plaque Psoriasis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Plaque Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TINEFCON

Tablets of 700 mg.

Group Type EXPERIMENTAL

TINEFCON

Intervention Type DRUG

Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TINEFCON

Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects of at least 18 years of age with clinical diagnosis of plaque psoriasis
* Subject who understand and willing to sign informed consent document before start of any study specific assessment

Exclusion Criteria

* Pregnant and lactating females
* Subject with active infection, acute or chronic due to bacteria, viruses, fungi or parasites (most notably tuberculosis, and chronic hepatitis B)
* Subject with heart failure (New York Heart Association class III or IV)
* Subject with demyelinating disease
* Subject with solid cancer or hematologic malignancy diagnosed within last 5 years with a potential for progression
* Women of childbearing potential \[defined as a sexually mature woman who has not undergone hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e. who has had menses any time in the preceding 24 consecutive months)\] and men, not agreeing to use adequate contraception (e.g., hormonal or barrier method of birth control or abstinence) after signing an informed consent document (ICD), during the duration of study participation and for at least 4 week after withdrawal from the study, unless they are surgically sterilized
* Subject with situations associated with a high risk of infection such as latent untreated tuberculosis, joint prosthesis infection within last 12 months, indwelling urinary catheter, uncontrolled diabetes, chronic obstructive pulmonary disease, skin ulcer
* Subject with known premalignant lesions (such as polyps in the colon or urinary bladder, cervical dysplasia and myelodysplasia)
* Subject known to be seropositive and/or clinically suspected to have the human immunodeficiency virus infection
* Subject with any condition that might make it difficult for the subject to participate in the study, at the discretion of the Investigator.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Piramal Enterprises Limited

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dr. Sharmila Patil

Role: PRINCIPAL_INVESTIGATOR

D.Y.Patil Medical college and Hospital, Dept. of Dermatology & STD,Sector-5, Nerul, Navi Mumbai

Dr. Jerajani

Role: PRINCIPAL_INVESTIGATOR

Lokmanya Tilak Municipal Medical College & General Hospital, Department of Dermatology, First Floor, College Building,Sion, Mumbai-400022 India

Dr. Saple

Role: PRINCIPAL_INVESTIGATOR

Dr. Saple's clinic, 88, 3rd Lane, Hindu Colony, Near Bhagini Samaj, Dadar (East), Mumbai-400014

Dr.Ranjan Rawal

Role: PRINCIPAL_INVESTIGATOR

Sheth VS General Hospital, Department of Dermatology, Ellis Bridge, Ahmedabad -380006, Gujrat, India

Dr Sudhakar Grandhi

Role: PRINCIPAL_INVESTIGATOR

Medipoint Hospitals Pvt. Ltd.,Pentagon Research Pvt. Ltd, 241/1, New DP Road, Aundh, Pune-411007, Maharashtra

Dr Sushil Pande

Role: PRINCIPAL_INVESTIGATOR

NKP Salve Institute and Lata Mangeshkar Hospital,Nagpur

Dr. Torsekar

Role: PRINCIPAL_INVESTIGATOR

Rajiv Gandhi Medical College & CSMH,Department of Dermatology, Kalwa, Thane

Dr. C.R. Srinivas

Role: PRINCIPAL_INVESTIGATOR

PSG Hospital,Department of Skin & STD,Avinashi Road, Peelamedu, Coimbatore, Tamilnadu-641004

Dr. DVS Pratap

Role: PRINCIPAL_INVESTIGATOR

Durgabai Deshmukh Hospital & Research Center, Andhramahila Sabha Road, Vidyanagar, University Road,Hyderabad

Dr. Aruna Samarth

Role: PRINCIPAL_INVESTIGATOR

Sai Skin Care Clinic, H.No.:2-1-409, Nallakunta, O.U.Road, Hyderabad

Dr. Kanwar

Role: PRINCIPAL_INVESTIGATOR

Postgraduate Institute of Medical Education and Research,Department of Dermatology ,Venerology & Leprology,Sector-12-Chandigarh

Dr. Meetesh Agarwal

Role: PRINCIPAL_INVESTIGATOR

178/DH Sector, Scheme No. 74, Vijaynagar, Indore 452 2010

Dr. Kailash Bhatia

Role: PRINCIPAL_INVESTIGATOR

Bhatia Skin Center,124-128, Anand Bazar, Bima Nagar, Indore

Dr. Parmjit Singh Walia

Role: PRINCIPAL_INVESTIGATOR

DR WALIA'S SKIN & LASER CLINIC, SCF - 30, PHASE

Dr. Bhavesh Swarnkar

Role: PRINCIPAL_INVESTIGATOR

Swarnkar Superspeciality Centre,84,Shreenagar Main,Regency Avenue,Ground Floor, Near Anand Bazar,Indore

Dr. Sandesh Gupta

Role: PRINCIPAL_INVESTIGATOR

Skin & Laser Center,F-12/10 Krishna Nagar, New Delhi

Dr. Puneet Goyal

Role: PRINCIPAL_INVESTIGATOR

Renova Skin & Laser Clinic,Sector 9, Shopping Centre,Opposite Meera Marg, Madhyam Marg, Mansarovar, Jaipur

Dr.Rizwan Haq

Role: PRINCIPAL_INVESTIGATOR

Radiance Skin Care Clinic, Opp. Muslim Library,Tekdi Road, Sadar, Nagpur

Dr Vikrant Saoji

Role: PRINCIPAL_INVESTIGATOR

Navprabhat Chambers,Opp. Tarun Bharat,Central Bazar Road,Ramdaspeth, Nagpur

Dr.B. Leelavathy

Role: PRINCIPAL_INVESTIGATOR

M.S. Diabetes and Shirdi Skin care centre 6/1, 80 Feet Road, Opp. Krishna Sagar Hotel, Indiranagar, Bangalore

Dr Titarmare

Role: PRINCIPAL_INVESTIGATOR

Skin Care Clinic, Consultant Dermatologist &Venerologist,Akshay Towers(Basement), Umrer Road,Sakkardhara Square, Nagpur

Dr Shatrughan Sahay

Role: PRINCIPAL_INVESTIGATOR

Sri Skin Care & Laser Clinic,Netaji Subash Chandra Bose Complex, Tulsidas Marg (Opp. Charak Pathalogy) Chowk-Lucknow

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Durgabai Deshmukh Hospital & Research Center

Hyderabad, Andhra Pradesh, India

Site Status

Postgraduate Institute of Medical Education and Research,Department of Dermatology ,Venerology & Leprology

Chandigarh, Chandigarh, India

Site Status

Sheth VS General Hospital, Department of Dermatology

Ahmedabad, Gujarat, India

Site Status

M.S. Diabetes and Shirdi Skin care centre

Bangalore, Karnataka, India

Site Status

Bhatia Skin Center,124-128, Anand Bazar, Bima Nagar

Indore, Madhtya Pradesh, India

Site Status

Scheme No. 74, , Vijaynagar, ,

Indore, Madhya Pradesh, India

Site Status

Swarnkar Superspeciality Centre,84,Shreenagar Main,Regency Avenue,Ground Floor, Near Anand Bazar

Indore, Madhya Pradesh, India

Site Status

Sai Skin Care Clinic

Hyderabad, Maharashtra, India

Site Status

Dr. Saple's clinic

Mumbai, Maharashtra, India

Site Status

Lokmanya Tilak Municipal Medical College & General Hospital, Department of Dermatology, First Floor, College Building,Sion

Mumbai, Maharashtra, India

Site Status

Seth GS Medical College &KEM Hospital,Department of Dermatology

Mumbai, Maharashtra, India

Site Status

Dr.Vikrant Saoji,27, Navprabhat Chambers,Opp. Tarun Bharat,Central Bazar Road,Ramdaspeth

Nagpur, Maharashtra, India

Site Status

NKP Salve Institute and Lata Mangeshkar Hospital

Nagpur, Maharashtra, India

Site Status

Radiance Skin Care Clinic

Nagpur, Maharashtra, India

Site Status

Skin Care Clinic, Consultant Dermatologist &Venerologist

Nagpur, Maharashtra, India

Site Status

Medipoint Hospitals Pvt. Ltd

Pune, Maharashtra, India

Site Status

Rajiv Gandhi Medical College

Thāne, Maharashtra, India

Site Status

Skin & Laser Center,F-12/10 Krishna Nagar,

New Delhi, New Delhi, India

Site Status

Dr Walia'S Skin & Laser Clinic, Scf - 30, Phase- 3B-2, S.A.S. Nagar

Mohali, Punjab, India

Site Status

Renova Skin & Laser Clinic,Sector 9, Shopping Centre,Opposite Meera Marg, Madhyam Marg

Jaipur, Rajasthan, India

Site Status

PSG Hospital,Department of Skin & STD

Coimbatore, Tamil Nadu, India

Site Status

Sri Skin Care & Laser Clinic

Lucknow, Uttar Pradesh, India

Site Status

D.Y.Patil Medical college and Hospital, Dept. of Dermatology & STD,Sector-5, Nerul

Navi Mumbai, , India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TINEFCON/49/10

Identifier Type: -

Identifier Source: org_study_id